Form 4: Teladoc Health Interim CAO James L. Cave Reports Stock Transactions
SEC Form 4
James L. Cave, Interim CAO of Teladoc Health, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On May 31, 2024, James L. Cave, Interim CAO of Teladoc Health, exercised restricted stock units, converting them into common stock.
- He acquired 339, 1,001, 383, and 1,162 shares of common stock through the conversion of restricted stock units.
- On June 3, 2024, he sold 854 shares of common stock at a price of $11.157 per share.
- Following these transactions, Cave directly owns 12,479 shares of Teladoc Health common stock and holds derivative securities including 1,017, 0, 1,534 and 8,139 restricted stock units.
- The sale of shares was to cover tax withholding obligations related to the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the healthcare technology industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 04/01/2022 | Reporting person was granted 4,067 restricted stock units, vesting one-third on March 1, 2023, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 06/01/2022 | Reporting person was granted 4,002 restricted stock units, vesting in four substantially equal semiannual installments beginning on the six-month anniversary of the grant date. |
| 06/01/2022 | Reporting person was granted 4,598 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 13,951 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2023 | One-third of 4,067 restricted stock units vested. |
| 05/31/2024 | Date of earliest transaction; conversion of restricted stock units to common stock. |
| 03/01/2024 | One-third of 13,951 restricted stock units vested. |
| 06/03/2024 | Sale of 854 shares of common stock. |
| 06/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.